Holen Sie sich die Stockscreener-App
0.00
100.00%
-7.539
Schlusskurs vom Vortag:
$7.539
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$11.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.58M
KGV:
0.00
EPS:
-9.49
Netto-Cashflow:
$-6.79M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$14.59
Kintara Therapeutics Inc Stock (KTRA) Company Profile
Firmenname
Kintara Therapeutics Inc
Sektor
Branche
Telefon
(858) 350-4364
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 150, SAN DIEGO
Vergleichen Sie KTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTRA
Kintara Therapeutics Inc
|
0.00 | 11.99M | 0 | -10.58M | -6.79M | -5.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kintara Therapeutics Inc Stock (KTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-11-05 | Eingeleitet | Maxim Group | Buy |
Kintara Therapeutics Inc Aktie (KTRA) Neueste Nachrichten
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - The Eastern Progress Online
TuHURA Biosciences expects to complete enrollment for REM-001 study in Q4 - TipRanks
TuHURA Biosciences Advances Phase 3 Trial, Secures $36M Funding for Cancer Pipeline - StockTitan
TuHURA Biosciences Inc (HURA) Quarterly 10-Q Report - Quartzy
Kintara stock climbs 10% on TuHURA merger update - MSN
Can Kintara Therapeutics Inc (KTRA) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
TuHURA Biosciences finalizes merger, sets Phase 3 trial - Investing.com India
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - PR Newswire
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Lowenstein Represents Kintara Therapeutics in Merger with TuHURA Biosciences - Lowenstein Sandler LLP
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - AccessWire
Kintara approves 1-for-35 reverse stock split before merger - Investing.com India
Kintara Therapeutics Announces Stock Split Amid Merger - TipRanks
Kintara approves reverse stock split, rebrands as TuHURA Biosciences - Investing.com India
Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger - TipRanks
Kintara approves 1-for-35 reverse stock split before merger By Investing.com - Investing.com South Africa
Kintara approves reverse stock split, rebrands as TuHURA Biosciences By Investing.com - Investing.com Australia
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Kintara Therapeutics Inc (KTRA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - PR Newswire
Kintara amends CVR issuance terms ahead of TuHURA merger By Investing.com - Investing.com Canada
Kintara amends CVR issuance terms ahead of TuHURA merger - Investing.com India
Kintara Therapeutics Updates on Merger and CVR Issuance - TipRanks
The Significance of Moving Averages in Kintara Therapeutics Inc Inc. (KTRA) Price Performance - The InvestChronicle
Market Highlights: Kintara Therapeutics Inc (KTRA) Ends on a High Note at 0.20 - The Dwinnex
Kintara stock climbs 10% on TuHURA merger update (NASDAQ:KTRA) - Seeking Alpha
Kintara Therapeutics Inc (KTRA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Stockholders Fail to Approve Proposal to Reincorporate Nevada Corporation in Delaware - The National Law Review
Kintara Therapeutics Reveals Improved Financials, Merger Plans - Yahoo Finance
Ratios Reveal: Breaking Down Kintara Therapeutics Inc (KTRA)’s Financial Health - The Dwinnex
Are Kintara Therapeutics Inc (KTRA) shares a good deal now? - US Post News
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update - PR Newswire
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update - GuruFocus.com
Kintara shareholders approve key proposals; Charter change fails - Investing.com
Kintara shareholders approve key proposals; Charter change fails By Investing.com - Investing.com Australia
This trade activity should not be overlooked: Kintara Therapeutics Inc (KTRA) - SETE News
Financial Metrics Unveiled: Kintara Therapeutics Inc (KTRA)’s Key Ratios in the Spotlight - The Dwinnex
Kintara Therapeutics modifies merger terms with TuHURA Biosciences By Investing.com - Investing.com Canada
Kintara Therapeutics Inc Inc. (KTRA) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com India
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - Benzinga
Kinross Gold (NYSE:KGC) Lowered to Buy at StockNews.com - Defense World
Kintara Therapeutics announces special stockholder meeting - Investing.com
Viking Therapeutics Unusual Options Activity For September 24 - Benzinga
Results from Kintara Therapeutics Inc (KTRA) show risk - US Post News
Finanzdaten der Kintara Therapeutics Inc-Aktie (KTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):